MX2010011381A - Composiciones que comprenden farmacos levemente basicos y formas de dosificacion de liberacion controlada. - Google Patents

Composiciones que comprenden farmacos levemente basicos y formas de dosificacion de liberacion controlada.

Info

Publication number
MX2010011381A
MX2010011381A MX2010011381A MX2010011381A MX2010011381A MX 2010011381 A MX2010011381 A MX 2010011381A MX 2010011381 A MX2010011381 A MX 2010011381A MX 2010011381 A MX2010011381 A MX 2010011381A MX 2010011381 A MX2010011381 A MX 2010011381A
Authority
MX
Mexico
Prior art keywords
compositions
controlled
dosage forms
weakly basic
release dosage
Prior art date
Application number
MX2010011381A
Other languages
English (en)
Inventor
Venkatesh Gopi
Lai Jin-Wang
j stevens Philip
Original Assignee
Eurand Inc Star
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41164198&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2010011381(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eurand Inc Star filed Critical Eurand Inc Star
Publication of MX2010011381A publication Critical patent/MX2010011381A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Zoology (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)

Abstract

La presente invención se refiere a composiciones farmacéuticas y métodos para preparar dichas composiciones, que comprenden micropartículas que contienen un núcleo de fármaco levemente básico, una capa amortiguadora alcalina y un recubrimiento de liberación controlada. La presente invención también se refiere a las formas de dosificación farmacéuticas, incluidos los comprimidos de desintegración oral, comprimidos convencionales y cápsulas y métodos para su preparación.
MX2010011381A 2008-04-15 2009-04-15 Composiciones que comprenden farmacos levemente basicos y formas de dosificacion de liberacion controlada. MX2010011381A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4517008P 2008-04-15 2008-04-15
PCT/US2009/040608 WO2009129282A1 (en) 2008-04-15 2009-04-15 Compositions comprising weakly basic drugs and controlled-release dosage forms

Publications (1)

Publication Number Publication Date
MX2010011381A true MX2010011381A (es) 2011-03-02

Family

ID=41164198

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010011381A MX2010011381A (es) 2008-04-15 2009-04-15 Composiciones que comprenden farmacos levemente basicos y formas de dosificacion de liberacion controlada.

Country Status (19)

Country Link
US (1) US20090258066A1 (es)
EP (1) EP2276472B1 (es)
JP (2) JP5808670B2 (es)
KR (1) KR20110008036A (es)
CN (2) CN106389340A (es)
AR (1) AR071366A1 (es)
AU (1) AU2009236271B2 (es)
CA (1) CA2721083A1 (es)
CL (1) CL2009000903A1 (es)
CO (1) CO6300931A2 (es)
CR (1) CR11740A (es)
IL (1) IL208774A0 (es)
MX (1) MX2010011381A (es)
NZ (1) NZ588499A (es)
RU (1) RU2548748C2 (es)
SA (1) SA109300226B1 (es)
TW (1) TWI519322B (es)
WO (1) WO2009129282A1 (es)
ZA (1) ZA201007294B (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
DE102005005449A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
TWI519322B (zh) * 2008-04-15 2016-02-01 愛戴爾製藥股份有限公司 包含弱鹼性藥物及控制釋放劑型之組合物
CA2757979A1 (en) * 2009-04-09 2010-10-14 Alkermes Pharma Ireland Limited Controlled-release clozapine compositions
WO2011009604A1 (en) 2009-07-22 2011-01-27 Grünenthal GmbH Oxidation-stabilized tamper-resistant dosage form
CN107441058A (zh) * 2009-11-09 2017-12-08 惠氏有限责任公司 包衣药物球状体及消除或减少病症如呕吐和腹泻的用途
EP2506835B1 (en) 2009-11-30 2019-06-12 Adare Pharmaceuticals, Inc. Compressible-coated pharmaceutical compositions and tablets and methods of manufacture
US8529914B2 (en) * 2010-06-28 2013-09-10 Richard C. Fuisz Bioactive dose having containing a material for modulating pH of a bodily fluid to help or hinder absorption of a bioactive
US9011912B2 (en) 2010-10-07 2015-04-21 Abon Pharmaceuticals, Llc Extended-release oral dosage forms for poorly soluble amine drugs
US20120282335A1 (en) 2010-12-02 2012-11-08 Aptalis Pharmatech Inc. Rapidly dispersing granules, orally disintegrating tablets and methods
AR087360A1 (es) 2011-07-29 2014-03-19 Gruenenthal Gmbh Tableta a prueba de manipulacion que proporciona liberacion de farmaco inmediato
KR20140053158A (ko) 2011-07-29 2014-05-07 그뤼넨탈 게엠베하 즉시 약물 방출을 제공하는 탬퍼-저항성 정제
CN102579404A (zh) * 2012-01-17 2012-07-18 广州科的信医药技术有限公司 一种盐酸丙哌维林缓释胶囊及其制备方法
US9763928B2 (en) * 2012-02-10 2017-09-19 Niconovum Usa, Inc. Multi-layer nicotine-containing pharmaceutical composition
AU2014289187B2 (en) 2013-07-12 2019-07-11 Grunenthal Gmbh Tamper-resistant dosage form containing ethylene-vinyl acetate polymer
JP6238401B2 (ja) * 2013-10-28 2017-11-29 日本化薬株式会社 生理活性ペプチド徐放性微粒子及びその製造方法
MX371372B (es) 2013-11-26 2020-01-28 Gruenenthal Gmbh Preparacion de una composicion farmaceutica en polvo por medio de criomolienda.
WO2015120201A1 (en) * 2014-02-05 2015-08-13 Kashiv Pharma, Llc Abuse-resistant drug formulations with built-in overdose protection
TWI535784B (zh) 2014-08-26 2016-06-01 財團法人工業技術研究院 剪切增稠配方、及包含其之複合材料
US9132096B1 (en) 2014-09-12 2015-09-15 Alkermes Pharma Ireland Limited Abuse resistant pharmaceutical compositions
WO2017026950A1 (en) 2015-08-07 2017-02-16 Santa Farma Ilac San. A. S. Controlled release propiverine formulations
WO2017042325A1 (en) 2015-09-10 2017-03-16 Grünenthal GmbH Protecting oral overdose with abuse deterrent immediate release formulations
WO2020101586A1 (en) 2018-11-16 2020-05-22 Santa Farma İlaç Sanayi̇ A.Ş. Controlled release propiverine formulations
TR201918013A2 (tr) * 2019-11-19 2021-06-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Propi̇veri̇n veya propi̇veri̇ni̇n farmasöti̇k olarak kabul edi̇lebi̇li̇r bi̇r tuzunu i̇çeren pellet kompozi̇syonu
WO2022115056A1 (en) 2020-11-27 2022-06-02 Santa Farma Ilac Sanayii A.S. Sustained release formulation compositions comprising propiverine
WO2022132066A1 (en) * 2020-12-18 2022-06-23 Santa Farma Ilac Sanayii A.S. Homogenous compositions of propiverine hci formulations
CN112472715B (zh) * 2020-12-18 2023-06-23 华熙生物科技股份有限公司 一种碳酸氢钠肠溶胶囊及其制备方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3341416A (en) * 1963-12-11 1967-09-12 Ncr Co Encapsulation of aspirin in ethylcellulose and its product
GB2189699A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated acid-labile medicaments
GB2189698A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
SE9402431D0 (sv) * 1994-07-08 1994-07-08 Astra Ab New tablet formulation
SE9500422D0 (sv) * 1995-02-06 1995-02-06 Astra Ab New oral pharmaceutical dosage forms
DE10149674A1 (de) * 2001-10-09 2003-04-24 Apogepha Arzneimittel Gmbh Orale Darreichungsformen für Propiverin oder seinen pharmazeutisch annehmbaren Salzen mit verlängerter Wirkstoffreisetzung
US6663888B2 (en) * 2001-12-14 2003-12-16 Eurand Pharmaceuticals Ltd. Pulsatile release histamine H2 antagonist dosage form
MY148805A (en) * 2002-10-16 2013-05-31 Takeda Pharmaceutical Controlled release preparation
CL2004000983A1 (es) * 2003-05-08 2005-03-04 Altana Pharma Ag Composicion farmaceutica oral en forma de tableta que comprende a pantoprazol magnetico dihidratado, en donde la forma de tableta esta compuesto por un nucleo, una capa intermedia y una capa exterior; y uso de la composicion farmaceutica en ulceras y
DE10353186A1 (de) * 2003-11-13 2005-06-16 Röhm GmbH & Co. KG Mehrschichtige Arzneiform, enthaltend eine in Bezug auf die Wirkstoffabgabe modulatorisch wirkende Substanz
US20050214372A1 (en) * 2004-03-03 2005-09-29 Simona Di Capua Stable pharmaceutical composition comprising an acid labile drug
US8545881B2 (en) * 2004-04-19 2013-10-01 Eurand Pharmaceuticals, Ltd. Orally disintegrating tablets and methods of manufacture
RU2382637C2 (ru) * 2004-04-30 2010-02-27 Астеллас Фарма Инк. Фармацевтическая композиция для перорального введения в форме частиц с рассчитанным временем высвобождения и быстро распадающиеся таблетки, содержащие указанную композицию
US9884014B2 (en) * 2004-10-12 2018-02-06 Adare Pharmaceuticals, Inc. Taste-masked pharmaceutical compositions
EP2417969A1 (en) 2004-10-21 2012-02-15 Aptalis Pharmatech, Inc. Taste-masked pharmaceutical compositions with gastrosoluble pore-formers
WO2006046560A1 (ja) * 2004-10-29 2006-05-04 Taiho Pharmaceutical Co., Ltd. プロピベリン含有経口粉粒状製剤及びその製造法
US20060105038A1 (en) 2004-11-12 2006-05-18 Eurand Pharmaceuticals Limited Taste-masked pharmaceutical compositions prepared by coacervation
WO2006054513A1 (ja) * 2004-11-19 2006-05-26 Kissei Pharmaceutical Co., Ltd. 神経因性疼痛の予防又は治療剤
US9161918B2 (en) * 2005-05-02 2015-10-20 Adare Pharmaceuticals, Inc. Timed, pulsatile release systems
US20070141151A1 (en) * 2005-12-20 2007-06-21 Silver David I Lansoprazole orally disintegrating tablets
NZ570039A (en) * 2006-01-27 2011-07-29 Eurand Inc Drug delivery systems comprising weakly basic selective serotonin 5-HT3 blocking agent and organic acids
CN101410093A (zh) * 2006-01-27 2009-04-15 欧兰德股份有限公司 包含弱碱性药物和有机酸的药物递送系统
EP2012756A4 (en) 2006-04-20 2013-01-23 Inventia Healthcare Private Ltd MULTI-UNIT COMPOSITIONS
TWI519322B (zh) * 2008-04-15 2016-02-01 愛戴爾製藥股份有限公司 包含弱鹼性藥物及控制釋放劑型之組合物
NZ594311A (en) * 2009-02-04 2013-05-31 Astellas Pharma Inc Pharmaceutical composition comprising tamsulosin and solifenacin for oral administration

Also Published As

Publication number Publication date
EP2276472A4 (en) 2013-05-08
WO2009129282A1 (en) 2009-10-22
US20090258066A1 (en) 2009-10-15
JP5808670B2 (ja) 2015-11-10
JP2011516611A (ja) 2011-05-26
RU2548748C2 (ru) 2015-04-20
RU2010146173A (ru) 2012-05-20
ZA201007294B (en) 2011-12-28
CN106389340A (zh) 2017-02-15
EP2276472A1 (en) 2011-01-26
CL2009000903A1 (es) 2010-03-12
AU2009236271A1 (en) 2009-10-22
IL208774A0 (en) 2010-12-30
TW201006509A (en) 2010-02-16
AR071366A1 (es) 2010-06-16
JP2015098477A (ja) 2015-05-28
CN102006862A (zh) 2011-04-06
KR20110008036A (ko) 2011-01-25
CR11740A (es) 2011-01-21
SA109300226B1 (ar) 2014-09-02
NZ588499A (en) 2013-01-25
AU2009236271B2 (en) 2013-10-17
CA2721083A1 (en) 2009-10-22
TWI519322B (zh) 2016-02-01
EP2276472B1 (en) 2018-11-21
CO6300931A2 (es) 2011-07-21

Similar Documents

Publication Publication Date Title
MX2010011381A (es) Composiciones que comprenden farmacos levemente basicos y formas de dosificacion de liberacion controlada.
MX337603B (es) Composiciones y tabletas farmaceuticas con recubrimiento compresible y metodos de fabricacion.
UA106634C2 (uk) Тверда фармацевтична дозована форма
ZA200903929B (en) Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor
CO6440564A2 (es) Composiciones farmacéuticas de liberación inmediata que comprenden oxicodona y naloxona
UA96306C2 (ru) Способ получения твердой пероральной фармацевтической дозированной формы, резистентной против повреждения
MA32692B1 (fr) Procede de liberation d'une composition pharmaceutique a un patient qui en a besoin
AU2007211091A8 (en) Drug delivery systems comprising weakly basic selective serotonin 5-HT3 blocking agent and organic acids
MX2007004987A (es) Nuevas formulaciones de tabletas de liberacion modificada para inhibidores de bomba de protones.
FI2508188T3 (fi) Dapagliflotsiinipropyleeniglykolihydraattia sisältäviä farmaseuttisia formulaatioita
MX345942B (es) Composiciones de tabletas que se desintegran oralmente que comprenden combinaciones de farmacos en dosis alta y baja.
IL199472A0 (en) Non-effervescent, orally disintegrating solid pharmaceutical dosage forms, processes for the preparation of the same and uses thereof
TR201909173T4 (tr) İşlevselleştirilmiş kalsiyum karbonat içeren hızlı parçalanan katı dozaj formundaki formülasyon ve bunun üretim yöntemi.
EA200702627A1 (ru) Дозированные формы для перорального применения, содержащие прогестерон, и способы их изготовления и использования
MX2012003082A (es) Composiciones farmaceuticas para reducir la absorcion rapida de la dosis inducida por el alcohol.
EA201200937A1 (ru) Твердая лекарственная форма тикагрелора
SI1746980T1 (sl) Farmacevtska dozirna oblika ki obsega pelete kot tudi postopek za njeno pripravo
PH12014501408A1 (en) Immediate release multi unit pellet system
BRPI0925315B8 (pt) composição farmacêutica de dosagem fixa, oral, sólida, estável na forma de um comprimido de monocamada, processo para a preparação da mesma e uso de irbesartan e besilato de amlodipina
PH12015500823A1 (en) Modified release formulations for oprozomib
WO2010012459A3 (en) A process for the preparation of solifenacin salts and their inclusion into pharmaceutical dosage forms
EA201200485A1 (ru) Перорально распадающаяся фармацевтическая лекарственная форма, содержащая арипипразол
WO2013098268A3 (en) Tablets and dry-coated agents
EP2101742B8 (en) Pharmaceutical composition containing clopidogrel hydrogenesulphate of polymorph 1 form
RU2012136190A (ru) Фармацевтический состав для профилактики или лечения артрозоартрита, содержащий ребамипид в качестве активного ингредиента

Legal Events

Date Code Title Description
HC Change of company name or juridical status

Owner name: MICROSOFT TECHNOLOGY LICENSING, LLC

FG Grant or registration